Subject Index Vol. 75, Suppl. 1, 2008
Soo Ryang Kim, Tomoyuki Nagai(National Archives and Records Administration), Yo Sasaki, Satoshi Goshima, Chie Tatsumi(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hiroshi Kondo, Hiroko Oka, Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Myeong‐Jin Kim(Ulsan College), Yasunori Minami(Kindai University), Kwang‐Hyub Han(Yonsei University), Shunsuke Takahashi(Kanagawa Dental University), Toshihito Seki(Kansai Medical University), Hobyung Chung(Kindai University), Okio Hino(Juntendo University), Yukio Osaki, Emi Ishikawa, Taisuke Ueda, Kazuomi Ueshima(Kindai University), Kinuyo Hatanaka(Union Hospital), Syunsuke Takahashi, Takashi Matsunaga(Shiga University of Medical Science), Jin‐Young Choi(Yonsei University Health System), Tatsuo Inoue, Sun Young Choi, Masayuki Kanematsu(Gifu University), Young Hwa Chung, Seiji Haji(Kindai University), Hyo Suk Lee, Hiroshi Kasugai(Osaka International Cancer Institute), Kiyoshi Maekawa(Kindai University), Yong Eun Chung(Yonsei University), Haruo Watanabe, Yusuke Tsuge
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Autophagy-deficient mice develop multiple liver tumors
|Genes & Development|2011|1.3k